Evaluation of Drug Resistance in Patients With Metastatic Breast Cancer

Status unconfirmed · Phase 2

Conditions studied: Breast Cancer

In brief

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Some patients may develop a resistance to chemotherapy drugs. PURPOSE: Phase II trial to determine the reliability of a test for measuring drug resistance to paclitaxel in patients with metastatic breast cancer.

Key facts

Study ID

NCT00003253

Run by

Oncotech

People needed

100

Starts

1997-07-01

Last updated by the study team

2013-12-19

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Pacific Coast Hematology/Oncology Medical Group — Fountain Valley, California, United States
• Long Beach Memorial Breast Center — Long Beach, California, United States
• USC/Norris Comprehensive Cancer Center and Hospital — Los Angeles, California, United States
• Jonsson Comprehensive Cancer Center, UCLA — Los Angeles, California, United States
• Chao Family Comprehensive Cancer Center — Orange, California, United States
• Howard University — Washington D.C., District of Columbia, United States
• Louisiana State University Health Sciences Center - Shreveport — Shreveport, Louisiana, United States
• Palmetto Hematology/Oncology Associates — Spartanburg, South Carolina, United States
• University of Texas - MD Anderson Cancer Center — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.